Literature DB >> 1280751

Measurement of serum cytokine levels in patients with myelodysplastic syndromes.

G E Verhoef1, P De Schouwer, J L Ceuppens, J Van Damme, W Goossens, M A Boogaerts.   

Abstract

Sera of 25 healthy controls and 75 patients suffering from myelodysplastic syndromes (MDS) were investigated for serum concentration of interleukin-1 alpha (IL-1 alpha), IL-3, IL-6, granulocyte-colony-stimulating factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), erythropoietin (Epo), and tumor necrosis factor-alpha (TNF-alpha). According to French-American-British (FAB) classification, 21 refractory anemia (RA), seven refractory anemia with ring sideroblasts (RARS), 15 chronic myelomonocytic leukemia (CMML), 12 refractory anemia with excess of blasts (RAEB), and 20 RAEB in transformation (RAEBt) were examined. TNF-alpha levels were inversely correlated with lower levels of hemoglobin concentration (r = -0.31, p = 0.005), irrespective of the requirements for transfusion in anemic MDS patients. Significant differences in TNF-alpha levels between CMML (26.2 +/- 5.9 pg/ml) and the FAB subgroups (16.1 +/- 1.6 pg/ml) were detected. There was an overall inverse relationship between the level of erythropoietin and the degree of anemia, but a wide range of Epo response between patients with similar hemoglobin concentrations. Serum levels of IL-1 alpha and GM-CSF were undetected in most of the patients. In 57% of the samples there were detectable levels of G-CSF, without a correlation of the serum levels with blood cell counts, nor with any of the FAB subcategories. Overall, 29% and 25% of the patient sera exhibited elevated IL-3 and IL-6 levels, respectively. There was no correlation of the serum levels with any of the blood counts, other cytokines, nor FAB subcategories. In conclusion, simple negative feedback mechanism between a specific cytokine and the production of blood cells seems not to be the case in MDS, except for red cell production and erythropoietin concentration. Our data may suggest the involvement of TNF-alpha in the pathogenesis of anemia in MDS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280751

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  26 in total

1.  Biological and clinical significance of clonogenic assays in patients with myelodysplastic syndromes.

Authors:  D Marisavljević; Z Rolović; D Sefer; N Basara; D Ilić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

2.  Going from genes to proteins in myelodysplastic syndromes.

Authors:  Arnold Ganser; Michael A Morgan; Eva M Weissinger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-19       Impact factor: 11.205

Review 3.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma.

Authors:  Vladimir Jurisić; Milica Colović
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 5.  Immunologic aspects of hypoplastic myelodysplastic syndrome.

Authors:  Rodrigo T Calado
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

6.  Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome.

Authors:  L Molnár; T Berki; A Hussain; P Németh; H Losonczy
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

Review 7.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

8.  Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.

Authors:  Frédéric Baron; Stefan Suciu; Sergio Amadori; Petra Muus; Heinz Zwierzina; Claudio Denzlinger; Michel Delforge; Antoine Thyss; Dominik Selleslag; Karel Indrak; Gert Ossenkoppele; Theo de Witte
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

9.  Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha.

Authors:  J P Maciejewski; C Selleri; T Sato; H J Cho; L K Keefer; C F Nathan; N S Young
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 10.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.